FDA PATIENT REPRESENTATIVE PROGRAM

Recruitment of and promoting the retention of patient advocates who will advise the U.S. Food and Drug Administration (FDA) on new and already approved medical products, drugs, biologics, and medical devices, and who will provide advice to FDA early in the regulatory medical product development and review process

Training, including distributing course material in connection therewith, of patient advocates who will advise the U.S. Food and Drug Administration (FDA) on new and already approved medical products, drugs, biologics, and medical devices, and who provide advice to FDA early in the regulatory medical product development and review process